Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

ent for the control group (p=0.83) were maintained at 12 months. In addition, nine-month stent thrombosis rates for both groups were low and similar for the TAXUS Liberte Stent (0.8 percent) and control stent (0.7 percent, p=1.0).

"ATLAS clinical outcomes highlight that despite more complex lesions, the TAXUS Liberte Stent performed extremely well and achieved similar rates of death, myocardial infarction and repeat procedures compared to an historical TAXUS Express control," said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, Takoma Park, Maryland, and co-principal investigator of the TAXUS ATLAS trial.

Data reported in the JACC article showed the TAXUS Liberte Stent was associated with significantly shorter procedural times. The study documented shorter average procedure times of 47.8 minutes for TAXUS Liberte Stent versus 53.0 minutes in the control arm (p=0.0052). The need to use additional stents due to procedural complications was reduced by nearly 50 percent in the TAXUS Liberte Stent group (3.1 percent) versus control (6.0 percent) (p=0.0038).

"The TAXUS Liberte Stent represents the latest innovation of our drug-eluting stent pipeline and we are pleased that the TAXUS ATLAS results confirm its positive performance," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "It is also further testament to the leadership of Boston Scientific that we are able to take a proven drug like paclitaxel and successfully transition it to an even more deliverable platform such as the Liberte Stent."

The Company received the CE Mark for the TAXUS Liberte stent in Europe and other international markets in September 2005, and it is currently the market-leading drug-eluting stent outside the United States. The TAXUS Liberte stent is currently pending approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

Boston
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... YORK, Oct. 26, 2011 One week after a ... most serious of skin cancers, which causes 8,000 U.S. ... Skin Association (ASA), a collaboration of patients, families, advocates, ... scientists who have made groundbreaking discoveries and unique contributions ...
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that its ... $0.08 per share, payable on December 13, 2011 ... Perrigo Company is a leading global ... and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional ...
Cached Medicine Technology:American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 2American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 3
(Date:7/9/2014)... in Russia might contribute to HIV transmission and ... researchers from Boston University Schools of Medicine and ... State University, sought to discover the effect police ... cohort of HIV-positive people with lifetime of injection ... police were more likely to share needlesincreasing HIV ...
(Date:7/9/2014)... news release is available in French . ... factors in 14 year old teens, including brain structure and ... 70% accuracy who will go on to develop binge drinking ... of conscientiousness, and other variables such as life events and ... of binge drinking. Whether or not the child had ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... Services Outside of Houston PHOENIX, May 6 ... M. D. Anderson Cancer Center announced they will create the ... Arizona,s leading provider of health care and the nation,s leading ... unprecedented level of cancer care in Arizona.Located at US 60 ...
... May 6 The healthcare industry in ... inequalities in access to care. The public ... of the population, yet accounts for around ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Public-private partnerships offer an innovative means ...
... wife Ellen honored for generous contribution to New York University College ... ... Dr. Jan Linhart, D.D.S. and his wife, Ellen Linhart, have established ... Program at Dr. Linhart’s alma mater. In honor of this act ...
... with a humanitarian award at a glittering ceremony in London last night. ... ... of the world,s largest hospital ship charity were honored with a humanitarian ... , , ,The annual Variety Club International Humanitarian Award , whose ...
... Max Muscle Sports Nutrition,s newest product innovation is L-Tox, for advanced ... along with protective and regenerative factors. , ... Anaheim, ... Administration (FDA) www.fda.gov issued a stop product use directive ...
... small non-profit Ohio Biotech firm, has confirmed that they have decoded ... currently reported Swine Flu outbreak. , ... Albany, Ohio ... of infection and the first reported American death from the new ...
Cached Medicine News:Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 2Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 3Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 2Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 3Health News:Manhattan Dentist Inducted Into The Sir Harold Acton Society 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 3Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 4Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 2Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 3Health News:BioTech Firm Decodes Current Swine Flu BioMarkers 2Health News:BioTech Firm Decodes Current Swine Flu BioMarkers 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: